Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Hydrochlorothiazide

Hydrochlorothiazide

Hydrochlorothiazide is a diuretic medication commonly used to treat high blood pressure, heart failure, and edema.
It works by inhibiting the reabsorption of sodium and chloride in the kidney, leading to increased urine output.
This class of drugs, known as thiazide diuretics, are often prescribed in combination with other antihypertensive medications to manage hypertension more effectively.
Hydrochlorothiazide may also be used off-label to treat certain kidney and liver conditions.
Researchers can utilize PubCompare.ai's AI-driven platform to optimize their Hydrochlorothiazide research protocols and enhance reproducibility, locating relevant protocols from literature, preprints, and patents, and using innovative comparison tools to identify the best protocols and products.
This can help streamline research efficiently and effeciently.

Most cited protocols related to «Hydrochlorothiazide»

1
Longitudinal Assessment of Bariatric Surgery
Cited 10 times
Between November 2006 and February 2009, participants (n=64) enrolled in the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) at Weill Cornell Medical College and University of Pittsburgh Medical Center sites were enrolled in this ancillary study [12 (link)–14 (link)]. Due to recruiting delays, 41 additional participants were enrolled through December 2009 for a total of 105 participants, 53 from Weill Cornell and 52 from Pittsburgh.
Only Weill Cornell subjects were included in this analysis because BIA and reference measurements were not collected concomitantly in Pittsburgh. Three participants did not undergo bariatric surgery and were excluded, leaving an analysis sample of 50. All studies were approved by the Institutional Review Board of St. Luke’s-Roosevelt Hospital, and written informed consent was obtained.
Baseline measures were obtained on average 1.3 week before surgery (T0; range 0–11 week) and postoperative measures were approximately 12 months later (T12; range 10.6–17.7 months) at St. Luke’s-Roosevelt Hospital. A self-report medication log was obtained and checked against pill bottles and medical records when available. Exclusion criteria included pregnancy, abnormal thyroid or cortisol levels, and self-report of medications known to influence body composition (e.g., diuretics and corticosteroids). After chart abstraction, four subjects were identified to be on hydrochlorothiazide, a diuretic, and at baseline.
Weight (Weight Tronix, New York, NY; and Scale-Tronix, Wheaton, IL), height (Holtain; Crosswell, Wales-New York), BIA (Model TBF-310, Tanita Inc., Arlington Heights, IL), and body density (Bod Pod; (Cosmed, Chicago, IL; software version 2.3) [15 (link), 16 (link)] measurements were obtained [17 (link)]. TBW was measured using a D2O (~1 g/kg) oral dose administered after a venous blood sample was taken from an antecubital vein. After 3 h, a second blood sample was obtained (see online supplementary materials for details). A 3C model was used to estimate fat mass [18 (link)]: fat (kg)=2.122×(BW/d) −0.779×TBW −1.356×BW, where BW is the body weight in kilograms, d is the body density derived from BodPod, and TBW is the total body water in kilograms.
Widen E.M., Strain G., King W.C., Yu W., Lin S., Goodpaster B., Thornton J., Courcoulas A., Pomp A, & Gallagher D. (2014). Validity of Bioelectrical Impedance Analysis for Measuring Changes in Body Water and Percent Fat After Bariatric Surgery. Obesity surgery, 24(6), 847-854.
Publication 2014
Adrenal Cortex Hormones Bariatric Surgery BLOOD Body Composition Body Weight Contraceptives, Oral Diuretics Ethics Committees, Research Human Body Hydrochlorothiazide Hydrocortisone Operative Surgical Procedures Pharmaceutical Preparations Pregnancy Thyroid Diseases Veins Water, Body
2
Pharmacogenomic Evidence Assessment Pipeline
Cited 9 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Cardiovascular Agents Genetic Diversity Hydrochlorothiazide Muscle Rigidity Patients Pharmaceutical Preparations Phenotype Physicians
3
Cardiac Function in RVH Pig Model
Cited 8 times
Domestic pigs were randomized to control, RVH, and RVH treated with Valsartan (320 mg/day; RVH+Valsartan) or triple-therapy (Reserpine+hydralazine+hydrochlorothiazide, RVH+TT) for 4 wks post 6-wks of RVH (n=7 each). Cardiac function and myocardial oxygenation were then studied in-vivo using multi-detector computer tomography (CT) and blood oxygen level dependent (BOLD)-magnetic resonance imaging (MRI), respectively, and microvascular architecture ex-vivo with micro-CT. Myocardial protein expression and staining were measured ex-vivo. (Detailed descriptions of all experimental methods are included in the Online-only Data Supplementhttp://hyper.ahajournals.org).
Zhang X., Li Z.L., Crane J.A., Jordan K.L., Pawar A.S., Textor S.C., Lerman A, & Lerman L.O. (2014). VALSARTAN REGULATES MYOCARDIAL AUTOPHAGY AND MITOCHONDRIAL TURNOVER IN EXPERIMENTAL HYPERTENSION. Hypertension, 64(1), 87-93.
Publication 2014
Blood Oxygen Levels Cell Respiration Heart Hydralazine Hydrochlorothiazide Myocardium Proteins Reserpine Sus scrofa domestica Therapeutics Tomography Valsartan
4
Hypertension Management with Home Monitoring
Cited 8 times
The PEAR study [17 (link)]http://clinicaltrials.gov/ct2/show/NCT00246519 was approved by the Institutional Review Board at each site, and all participants gave informed consent. At an initial consent and screening visit, trained study personnel administered standardized questionnaires, performed a limited physical examination, and obtained blood and urine samples for testing to establish eligibility for participation [11 (link)]. Participants were provided an automated sphygmomanometer (MicroLife 3 AC1-PC, Minneapolis MN), the adequacy of which has been previously validated [18 (link)], and withdrawn from previous antihypertensive drug therapy. The device was set to measure BP in triplicate with each activation and to store the average systolic and diastolic BPs and the time of each set of measurements. Participants were instructed to take readings daily in the seated position, one set of three readings in the morning upon arising from bed and a second set in the evening just before retiring. At subsequent study visits (prior to randomization and at the end of therapy), an additional set of three readings was obtained seated (> 5 minutes) in the office using the home monitor. In addition, 24-hour ambulatory BP recordings were obtained at these visits using Spacelabs (Redmond WA) ambulatory monitors, model 90207, the adequacy of which has been previously validated [19 (link)]. Participants were instructed to conduct their usual daily activities while wearing the monitor, which was set to record BP four times per hour during the day (6 AM to 10 PM) and twice per hour during the night (10 PM to 6 AM). The average (± standard deviation) number of ambulatory measurements was 67 ± 10 during daytime hours and 15 ± 3 during nighttime hours.
At the end of the drug-free washout period, fasting blood samples were drawn in the seated position after ambulation for measurement of plasma renin activity [11 (link)]. To qualify for randomization, the average home diastolic BP in the previous week had to be ≥85 mmHg (consisting of at least five morning and five evening sets of readings) and the average office diastolic BP ≥ 90 mmHg. Participants received either atenolol or hydrochlorothiazide, starting at 50 mg or 12.5 mg daily, respectively, for two weeks, after which, if BP remained > 120/70 mmHg, the doses were increased to 100 mg or 25 mg daily, respectively, for six additional weeks.
Turner S.T., Schwartz G.L., Chapman A.B., Beitelshees A.L., Gums J.G., Cooper-DeHoff R.M., Boerwinkle E., Johnson J.A, & Bailey K.R. (2012). Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. Journal of Translational Medicine, 10, 47.
Full text: Click here
Publication 2012
Antihypertensive Agents Atenolol BLOOD Diastole Eligibility Determination Ethics Committees, Research Hydrochlorothiazide Medical Devices Pears Pharmaceutical Preparations Pharmacotherapy Physical Examination Plasma Pressure, Diastolic Renin Sitting Sphygmomanometers Systole Therapeutics Urinalysis
5
Comparing Self-Reported and Pharmacy-Recorded Drug Use
Cited 7 times
The linked information relevant to this study consisted of anonymized identifier codes, ATC codes, dispensing dates, date of entry in the IADB database, sex and age at the time of the first visit at entry to the cohort. The very first interview with the Lifelines Cohort Study participant was considered the baseline measurement and only the data of the baseline measurements (entry period) were used in the comparison of the two databases.
All drugs grouped at a second level of ATC coding were examined in the study. Besides the second level ATC codes, some specific drugs at the chemical level were included in the study. A top list of the several most commonly used drugs in the Netherlands including omeprazole, psylla seeds, macrogol, calcium, hydrochlorothiazide, metoprolol, enalapril, simvastatin, ketoconazole, triamcinolone, clobetasol, levothyroxine, oxazepam, temazepam, paroxetine, fluticasone, mometasone, salbutamol, salmeterol/fluticasone, desloratadine, artificial tears, carbasalate ca., diclofenac and ibuprofen was also examined.
The program SQL Server was used to compare the records of drugs for each participant. The acquired data was then categorized in true positives, true negatives, false positives (FPs) and false negatives (FNs). These values were given in cross-tables, which were used to calculate the concordance. Each of the four cells in these cross-tables were required to have at least 5 participants. If the number of participants was lower than 5 in one or more cells, the drug group or specific drug was disregarded.
In order to address the possible underlying cause of a low agreement, the FNs and FPs were examined. Over-reporting represents the number of FPs. This means that a number of participants reported the use of a certain drug group, while at the same time the prescription was not registered in the pharmacy records. On the other hand, under-reporting represents the number of FNs. This means that the participants did not report the use of a certain drug group, while at the same time the prescription was registered in the pharmacy records. If a drug group or specific drug showed a poor agreement and at the same time a high over-reporting, it could indicate that the database with the self-reported data is better capable in recording the use of this specific drug (or drug group).
Sediq R., van der Schans J., Dotinga A., Alingh R.A., Wilffert B., Bos J.H., Schuiling-Veninga C.C, & Hak E. (2018). Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: The PharmLines initiative. Clinical Epidemiology, 10, 981-989.
Publication 2018
Albuterol Calcium, Dietary Cells Clobetasol desloratadine Diclofenac Enalapril Fluticasone Fluticasone Salmeterol Hydrochlorothiazide Ibuprofen Ketoconazole Lubricant Eye Drops Metoprolol Mometasone Omeprazole Oxazepam Paroxetine Pharmaceutical Preparations Plant Embryos Polyethylene Glycols Simvastatin Temazepam Thyroxine Triamcinolone

Most recents protocols related to «Hydrochlorothiazide»

1
iPSCod Tubuloids Sodium Uptake Assay
iPSCod tubuloids were dissociated, grown to a confluent 2D monolayer in EM, and differentiated for 5 to 7 d as described above. Prior to the sodium uptake experiment, iPSCod tubuloids were preincubated for 30 min with either isotonic buffer (140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, with pH adjusted to 7.4 using Tris) or, to stimulate sodium uptake, hypotonic low-chloride buffer (70 mM Na+ D-gluconate, 2.5 mM K+ D-gluconate, 0.5 mM CaCl2, 0.5 mM MgCl2 and 2.5 mM HEPES, with pH set to 7.4 using Tris). The inhibitors (0.1 mM) hydrochlorothiazide, bumetanide, amiloride, and/or ouabain were included in the preincubation to inhibit the transporters/channels NCC, NKCC2, ENaC, and Na/K-ATPase, respectively. Ouabain was added to prevent basolateral removal of absorbed 22Na+. Same buffers including the radioactive tracer 22Na+ replaced the preincubation buffers and incubated for 30 min at 37 °C. The cells were washed three times in ice-cold isotonic or hypotonic buffer to remove any extracellular 22Na+ and lysed using 0.05% SDS for 30 min at 37 °C. Intracellular 22Na+ radioactivity was measured using a liquid scintillation counter (Hidex 300SL).
Yousef Yengej F.A., Jansen J., Ammerlaan C.M., Dilmen E., Pou Casellas C., Masereeuw R., Hoenderop J.G., Smeets B., Rookmaaker M.B., Verhaar M.C, & Clevers H. (2023). Tubuloid culture enables long-term expansion of functional human kidney tubule epithelium from iPSC-derived organoids. Proceedings of the National Academy of Sciences of the United States of America, 120(6), e2216836120.
Publication 2023
Amiloride Buffers Bumetanide Cardiac Arrest Cells Chlorides Cold Temperature gluconate HEPES Hydrochlorothiazide inhibitors Magnesium Chloride Membrane Transport Proteins Na(+)-K(+)-Exchanging ATPase Ouabain Protoplasm Radioactive Tracers Radioactivity Scintillation Counters Sodium Sodium Chloride Tromethamine
2
Bioequivalence of Amlodipine Combination Formulations
Cited 1 time
Data were obtained from eight bioequivalence trials that compared a test and a reference formulation of amlodipine combined with other antihypertensive or hypocholesterolemic agents. A single oral dose was administered under fasting conditions in all trials, which were phase I, open-label, single-center, crossover and randomized with two sequences and two periods for amlodipine. In clinical trial A, amlodipine/atorvastatin (10/10 mg) film-coated tablets were compared with Caduet® film-coated tablets (Pfizer S.A.) at the same dose. Amlodipine/valsartan (10 mg/160 mg) film-coated tablets were compared with Exforge® film-coated tablets (Novartis) at the same dose in clinical trial B. In clinical trials C, D and E, amlodipine/valsartan/hydrochlorothiazide (HTZ) (10/320/25 mg) film-coated tablets were compared with Exforge HCT® film-coated tablets (Novartis Europharm Limited) at the same dose. In clinical trials F, G and H, the test formulations were olmesartan/amlodipine/HTZ (40/10/12.5 mg) film-coated tablets, which were compared with Sevikar HCT® (Daiichi Sankyo Spain, S.A) or with Olmetec Plus® (Daiichi Sankyo Spain, S.A) and Norvas® (Pfizer S.A.) tablets, both 40/10/12.5 mg. The wash-out time between the two periods was 14 days for clinical trials A to E and 21 days for clinical trials F to H. In both periods in all clinical trials, volunteers were confined at UECHUP since 10 p.m. of the day before drug administration (day 0). Drug administration took place at 9:00 a.m. (day 1), and blood samples were extracted at different times for amlodipine plasmatic quantification and for genotyping. Volunteers from clinical trials C to H stayed at UECHUP until 9:30 p.m. (day 1) and volunteers from clinical trials A and B stayed until 9:30 a.m. (day 2). All the volunteers visited UECHUP for additional blood extractions at 24, 48 and 72 h after drug administration. The studies were blinded only for the plasma concentration determination of both formulations. In all of them, the test formulation was demonstrated to be bioequivalent to the reference for amlodipine. Therefore, the arithmetic mean of the pharmacokinetic parameters of both formulations was calculated for each volunteer.
Soria-Chacartegui P., Zubiaur P., Ochoa D., Villapalos-García G., Román M., Matas M., Figueiredo-Tor L., Mejía-Abril G., Calleja S., de Miguel A., Navares-Gómez M., Martín-Vilchez S, & Abad-Santos F. (2023). Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety. Pharmaceutics, 15(2), 404.
Full text: Click here
Publication 2023
Amlodipine amlodipine - atorvastatin Amlodipine-Valsartan Antihypertensive Agents BLOOD Caduet Exforge Exforge HCT Hydrochlorothiazide olmesartan Olmetec Plasma Voluntary Workers
3
Examining Pharmacists' Cardiovascular Medication Practices
A 35-year-old male was diagnosed with cardiac disease. In addition, the SP needed to refill the patient’s medications but had no prescription. Furthermore, the patient also had no known comorbidities or drug allergies. However, pharmacists were required to rule out any additional medical conditions, a history of medication use, and whether the patient had visited doctors or clinics. Additionally, on SP visits, pharmacists were expected to obtain valid prescriptions; otherwise, requested medications would not be filled. Furthermore, pharmacists should advise the SP not to take any additional cardiovascular-related medications without a prescription. The pharmacists were also expected to inform the patients that they should be monitored and followed up on a regular basis.
Three visits were made in three weeks, one week each, using three different scenarios. During the study period, the SP visited each CDRO three times to fully understand their actual practices.
In scenario 1, the SP was responsible for asking about two tracer POMs, such as captopril if enalapril was unavailable and atenolol if metoprolol was not available.
Scenario 2 also directed the SP to get information on two tracer POMs, such as propranolol and hydrochlorothiazide (HCT).
In scenario 3, the SP was instructed to ask about three tracer POMs, such as furosemide, spironolactone, and atorvastatin or simvastatin if atorvastatin was unavailable.
The SP data intended to determine the extent of CDROs' non-prescription cardiovascular medication dispensing and counseling practices were filled. The self-reported responses were then compared to the SP-based dispensing practice.
Sendekie A.K., Ergena A.E., Belachew E.A., Kasahun A.E., Teklie M.T, & Netere A.K. (2023). Extent of cardiovascular medications dispensing practice without a prescription: Self-reported and simulated patient-based study at community pharmacies in Northwest Ethiopia. Journal of Pharmaceutical Policy and Practice, 16, 28.
Full text: Click here
Publication 2023
Atenolol Atorvastatin Captopril Cardiovascular Agents Cardiovascular System Drug Allergy Drugs, Non-Prescription Enalapril Furosemide Heart Diseases Hydrochlorothiazide Males Metoprolol Patients Pharmaceutical Preparations Physicians Prescription Drugs Propranolol Simvastatin Spironolactone
4
Antihypertensive Medication Use Assessment
We obtained information on antihypertensive medication use from the questionnaire including the two parts. First, answered “yes” to “Are you now taking prescribed medication for high BP?” (13 ). Second, participants showed the container of prescription and non-prescription medications and supplements taken in the previous 30 days (15 ). The antihypertensive medication was classified using the Multum Lexicon 3-level nested category system, and all reported drug names were recorded as standard generic drugs. The fixed-dose combination (FDC) products were divided into individual generic ingredients (e.g., irbesartan/hydrochlorothiazide was classified into two separate compounds, “irbesartan” and “hydrochlorothiazide”). There are four classes of antihypertensive agents: ACEi/ARB, diuretics, beta-blockers (BB), and calcium channel blockers (CCB). In the current analysis, ACEi and ARB were classified into one group, and diuretics (thiazide, loop, and potassium-sparing) as one group.
Li F., Sun A., Wu F., Zhang D, & Zhao Z. (2023). Trends in using of antihypertensive medication among US CKD adults, NHANES 2001–2018. Frontiers in Cardiovascular Medicine, 10, 990997.
Full text: Click here
Publication 2023
Adrenergic beta-Antagonists Antihypertensive Agents Calcium Channel Blockers Dietary Supplements Diuretics Drugs, Non-Prescription Generic Drugs Hydrochlorothiazide Irbesartan Pharmaceutical Preparations Potassium Thiazides
5
Intensive Blood Pressure Intervention and Cognitive Outcomes
Enrollment started on January 10 and ended on December 31, 2017. Algorithms for BP intervention and monitoring in STEP have been published previously (detailed information available in the Supplementary Appendix of STEP available at NEJM.org). In general, three major classes of antihypertensive agents, including olmesartan (an angiotensin receptor blocker), amlodipine (a calcium channel blocker), and hydrochlorothiazide were provided free to participants. Following randomization, antihypertensive regimens were adjusted based on office SBP measurements to meet the BP target at baseline and during the entire follow-up period. All participants received a cognitive screening test [Mini-Mental State Examination (12 (link)); MMSE] at baseline and years 1, 2, and 3 during follow-up. Cardiovascular events, which was a composite of stroke, acute coronary syndrome, acute heart failure, atrial fibrillation, coronary revascularization, or death from cardiovascular causes, were recorded during follow-up. As of December 31 2020, 343 events had been reported, revealing a clear cardiovascular benefit in the intensive-treatment group. On the advice of the Data and Safety Monitoring Committee, the trial was thus terminated. All participants were assigned the final MMSE test (Figure 1). All the authors take responsibility for the accuracy and integrity of the data. Data in this study will be obtained by other researchers through contacting the corresponding author.
Fan J., Bai J., Liu W, & Cai J. (2023). Effects of intensive vs. standard blood pressure control on cognitive function: Post-hoc analysis of the STEP randomized controlled trial. Frontiers in Neurology, 14, 1042637.
Full text: Click here
Publication 2023
Acute Coronary Syndrome Amlodipine Angiotensin Receptor Antagonists Antihypertensive Agents Atrial Fibrillation Calcium Channel Blockers Cardiovascular System Cerebrovascular Accident Cognitive Testing Congestive Heart Failure Heart Hydrochlorothiazide Mini Mental State Examination olmesartan Safety Treatment Protocols

Top products related to «Hydrochlorothiazide»

1
Hydrochlorothiazide by Merck Group
Sourced in United States, Germany, United Kingdom
Hydrochlorothiazide is a pharmaceutical ingredient commonly used in the manufacturing of diuretic medications. It functions as a thiazide-type diuretic, aiding in the regulation of fluid balance within the body.
2
Formic acid by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.
3
Methanol by Merck Group
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
4
Furosemide by Merck Group
Sourced in United States, Germany, Canada, United Kingdom
Furosemide is a diuretic medication commonly used in medical laboratories. It is a powerful loop diuretic that works by inhibiting the reabsorption of sodium, chloride, and water in the ascending limb of the loop of Henle in the kidney. This action leads to an increased excretion of water, sodium, and chloride.
5
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
6
Acetonitrile by Merck Group
Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia
Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.
7
Ammonium formate by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, China, India, Switzerland, Spain, Canada, Poland, Sao Tome and Principe, Belgium, Czechia, Netherlands, Macao, Austria, Sweden, Japan, Hungary, Australia, Ireland
Ammonium formate is a chemical compound that is commonly used in various laboratory applications. It is a crystalline solid that is soluble in water and other polar solvents. Ammonium formate serves as a buffer in analytical techniques and is also used as a mobile phase additive in liquid chromatography.
8
Amiloride by Merck Group
Sourced in United States, Germany, Italy, Sao Tome and Principe, United Kingdom, Macao, China, Denmark
Amiloride is a laboratory product manufactured by Merck Group. It is a small molecule compound primarily used as a research tool in scientific investigations. Amiloride functions as a potassium-sparing diuretic, inhibiting the sodium-hydrogen exchanger and the epithelial sodium channel.
9
Acetonitrile by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Belgium, Germany, Canada, Portugal, France, Australia, Spain, Switzerland, India, Ireland, New Zealand, Sweden, Italy, Japan, Mexico, Denmark
Acetonitrile is a highly polar, aprotic organic solvent commonly used in analytical and synthetic chemistry applications. It has a low boiling point and is miscible with water and many organic solvents. Acetonitrile is a versatile solvent that can be utilized in various laboratory procedures, such as HPLC, GC, and extraction processes.
10
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

More about "Hydrochlorothiazide"

Hydrochlorothiazide, often abbreviated as HCTZ, is a diuretic medication commonly used to manage high blood pressure (hypertension), heart failure, and edema (fluid retention).
This thiazide-based diuretic works by inhibiting the reabsorption of sodium and chloride in the kidneys, leading to increased urine output and fluid excretion.
Hydrochlorothiazide is frequently prescribed in combination with other antihypertensive drugs, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), to more effectively control hypertension.
This class of medications, known as thiazide diuretics, can also be utilized off-label to treat certain kidney and liver conditions.
Researchers exploring the use of Hydrochlorothiazide can leverage PubCompare.ai's AI-driven platform to optimize their research protocols and enhance reproducibility.
This platform enables researchers to locate relevant protocols from literature, preprints, and patents, and utilize innovative comparison tools to identify the best protocols and products.
This can help streamline research efficiently and effeciently, ensuring that studies are conducted with the most robust and reliable methods.
In addition to Hydrochlorothiazide, researchers may also be interested in exploring other related compounds, such as Formic acid, Methanol, Furosemide, DMSO, Acetonitrile, Ammonium formate, and Amiloride.
PubCompare.ai's platform can assist in identifying the most relevant protocols and best practices for working with these substances, further enhancing the efficiency and reproducibility of research efforts.
By incorporating these insights, researchers can effectively navigate the complexities of Hydrochlorothiazide research and maximize the impact of their studies.